about
An update of current treatments for adult acute myeloid leukemiaRUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.HOTAIR is upregulated in acute myeloid leukemia and that indicates a poor prognosis.Postremission sequential monitoring of minimal residual disease by WT1 Q-PCR and multiparametric flow cytometry assessment predicts relapse and may help to address risk-adapted therapy in acute myeloid leukemia patients.Minimal residual disease in acute myeloid leukemia--current status and future perspectives.Therapeutically targeting SELF-reinforcing leukemic niches in acute myeloid leukemia: A worthy endeavor?Frontline treatment of acute myeloid leukemia in adults.High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.Comparable outcomes between autologous and allogeneic transplant for adult acute myeloid leukemia in first CR.Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis.Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT.Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT.Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission.Long-Term Outcome of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Acute Myeloid Leukemia (AML)- Single Center Retrospective Analysis.
P2860
Q26776396-39C4800E-EA29-4929-9823-B60FB82E7E92Q27853381-2B0BA910-CF86-4CFB-8B34-4F0CD9C36620Q35919361-EA4056DC-89FE-4DD5-BAD3-F7C82822C78FQ36528379-BDB9371C-9DF1-4833-A28C-B64B809F9A87Q38494659-5B1C948A-1579-4C5A-8E0C-D1DB142F8ABDQ38715325-5F3FD9EA-8DBE-41CA-92B8-B1529B2C0B8FQ38767583-988D6B07-4D55-49D9-83A5-7A361097F793Q38809840-58BCF742-6121-44E0-A4A3-DBF78F49F639Q40064058-8B5C66F9-2627-473D-8A26-CB53406DCE32Q40197450-3B782F83-EEDA-424A-93FB-979B3AB95FA8Q41530049-07FD4EDB-97B8-4D2F-ACE6-C3881A2B0406Q42429593-1B28614C-68FE-4F65-87D4-CCA4AF2C9581Q48337179-417BA2BA-3BC2-40EB-BAEC-6E3C2AD0DD95Q49833698-51CEBA20-10E4-47F6-8E1A-643E5DE6D93DQ50555238-5BFBDCDC-41CC-4CA8-99D5-80C38065F47C
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Post-remission therapy for acute myeloid leukemia
@ast
Post-remission therapy for acute myeloid leukemia
@en
Post-remission therapy for acute myeloid leukemia
@nl
type
label
Post-remission therapy for acute myeloid leukemia
@ast
Post-remission therapy for acute myeloid leukemia
@en
Post-remission therapy for acute myeloid leukemia
@nl
prefLabel
Post-remission therapy for acute myeloid leukemia
@ast
Post-remission therapy for acute myeloid leukemia
@en
Post-remission therapy for acute myeloid leukemia
@nl
P2860
P1433
P1476
Post-remission therapy for acute myeloid leukemia
@en
P2093
R. F. Schlenk
P2860
P304
P356
10.3324/HAEMATOL.2014.114611
P407
P577
2014-11-01T00:00:00Z